New hope for stem cell transplant patients: simpler drug combo may reduce severe side effects
NCT ID NCT06252870
First seen Feb 01, 2026 · Last updated Jun 17, 2026 · Updated 18 times
Summary
This study tests two different pre-transplant conditioning plans combined with a single drug combination (cyclophosphamide and methotrexate) to prevent graft-versus-host disease (GVHD) in blood cancer patients receiving a stem cell transplant from a matched donor. About 82 adults aged 18-70 will take part. The goal is to see if this approach can reduce severe GVHD while allowing fewer long-term immune-suppressing drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Angers
RECRUITINGAngers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Brest
RECRUITINGBrest, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Nantes
RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.